Cortexyme (CRTX) News Today $0.79 +0.01 (+1.29%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsFinancialsInsider TradesTrendsStock AnalysisChartCompetitorsFinancialsInsider TradesTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period August 1, 2022 | marketscreener.comCortexyme : Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name - Form 8-K - Marketscreener.comJuly 27, 2022 | marketscreener.comCortexyme Completes Phase 1 Single, Multiple Ascending Dose Trial of Potential Alzheimer's Disease Treatment - Marketscreener.comJuly 27, 2022 | businesswire.comCortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 - Business WireJuly 27, 2022 | businesswire.comCortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 - Business WireJuly 27, 2022 | marketscreener.comCortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 - Marketscreener.comJuly 27, 2022 | finance.yahoo.comCortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 - Yahoo FinanceJuly 27, 2022 | finance.yahoo.comCortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588July 27, 2022 | finance.yahoo.comCortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022July 22, 2022 | streetinsider.comCortexyme (CRTX) Announces Resignation of EVP of Research and Development - StreetInsider.comJune 26, 2022 | gurufocus.comBragar Eagel & Squire, PC Is Investigating Agrify, CareDx, Medallion, and Cortexyme and Encourages Investors to Contact the Firm - GuruFocus.comJune 21, 2022 | benzinga.comCortexyme Announces Preclinical Data Demonstrating Efficacy Of Cor803 For The Treatment Of Coronavirus In - BenzingaJune 21, 2022 | nasdaq.comCortexyme : Preclinical Data Show Efficacy Of COR803 For Coronavirus Infections Treatment - NasdaqJune 21, 2022 | finance.yahoo.comCortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus InfectionsJune 13, 2022 | businesswire.comCortexyme Appoints June Bray to its Board of Directors - Business WireJune 13, 2022 | finance.yahoo.comCortexyme Appoints June Bray to its Board of Directors - Yahoo FinanceJune 13, 2022 | finance.yahoo.comCortexyme Appoints June Bray to its Board of DirectorsJune 11, 2022 | marketscreener.comCortexyme, Inc. Announces Resignation of Christopher Lowe as Chief Financial Officer - Marketscreener.comJune 10, 2022 | marketscreener.comCortexyme : Statement of Changes in Beneficial Ownership (Form 4) - Marketscreener.comMay 22, 2022 | businesswire.comCortexyme Successfully Completes Acquisition of Novosteo - Business WireMay 20, 2022 | nasdaq.comThis Is the Worst Type of Credit Card for Most Consumers - NasdaqMay 20, 2022 | finance.yahoo.comPPG Showcases Innovations in Paints, Coatings, Specialty Materials That Enhance Sustainability, Efficiency, Mobility - Yahoo FinanceMay 20, 2022 | marketscreener.comCortexyme : Completion of Acquisition or Disposition of Assets - Form 8-K - Marketscreener.comMay 20, 2022 | finance.yahoo.comCortexyme Successfully Completes Acquisition of Novosteo - Yahoo FinanceMay 20, 2022 | finance.yahoo.comCortexyme Appoints Dr. Philip Low to Its Board of DirectorsMay 13, 2022 | nasdaq.comPre-market Movers: EBET, AFRM, CELU, FIGS, LLAP… - NasdaqMay 12, 2022 | finance.yahoo.comCortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases - Yahoo FinanceMay 12, 2022 | finance.yahoo.comCortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic DiseasesMay 11, 2022 | streetinsider.comForm 10-Q Cortexyme, Inc. For: Mar 31 - StreetInsider.comMay 11, 2022 | streetinsider.comCortexyme Announces Agreement to Acquire Novosteo - StreetInsider.comMay 10, 2022 | bizjournals.comTuesday Digest: Prologis attempts hostile buyout of Duke; Salesforce's latest buy - San Francisco Business Times - The Business JournalsMay 10, 2022 | finance.yahoo.comCortexyme Announces Agreement to Acquire NovosteoMay 6, 2022 | benzinga.comBragar Eagel & Squire, P.C. Is Investigating Agrify, CareDx, Medallion, and Cortexyme and Encourages Investors to Contact the FirmMay 6, 2022 | finance.yahoo.comIs Cortexyme (NASDAQ:CRTX) In A Good Position To Deliver On Growth Plans?May 3, 2022 | gurufocus.comBragar Eagel & Squire, PC Is Investigating CareDx, Medallion, Cortexyme, and Corcept and Encourages Investors to Contact the Firm - GuruFocus.comMay 3, 2022 | benzinga.comThe Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Appl - BenzingaMay 3, 2022 | benzinga.comCortexyme Announces Further Layoffs, Chief Medical Officer LeavesMay 3, 2022 | marketscreener.comCORTEXYME, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers (form 8-K) - Marketscreener.comMay 1, 2022 | benzinga.comBragar Eagel & Squire, P.C. Is Investigating CareDx, Medallion, Cortexyme, and Corcept and Encourages Investors to Contact the FirmApril 28, 2022 | benzinga.comCortexyme, Inc. Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - BenzingaApril 25, 2022 | benzinga.comBragar Eagel & Squire, P.C. Is Investigating Cortexyme, Corcept, RBB, and Verra and Encourages Investors to Contact the FirmApril 25, 2022 | prnewswire.comThinking about buying stock in Cortexyme, Borqs Technologies, Sundial Growers, Nokia, or Nordic American Tanker? - PR NewswireApril 23, 2022 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cortexyme, Inc. - CRTX - BenzingaApril 15, 2022 | benzinga.comBragar Eagel & Squire, P.C. Is Investigating CareDx, Medallion, Cortexyme, and SelectQuote and Encourages Investors to Contact the FirmApril 15, 2022 | globenewswire.comBragar Eagel & Squire, PC Is Investigating CareDx, Medallion, Cortexyme, and SelectQuote and Encourages Investors to Contact the Firm - GlobeNewswireApril 11, 2022 | benzinga.comBragar Eagel & Squire, P.C. Is Investigating Medallion, Cortexyme, SelectQuote, and Corcept and Encourage - BenzingaApril 10, 2022 | globenewswire.comBragar Eagel & Squire, PC Is Investigating Medallion, - GlobeNewswireMarch 29, 2022 | marketbeat.comCortexyme (NASDAQ:CRTX) Downgraded to "Sell" at Zacks Investment ResearchZacks Investment Research downgraded shares of Cortexyme from a "hold" rating to a "sell" rating in a report on Tuesday.March 28, 2022 | globenewswire.comHAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Investigating Cortexyme, Inc. (CRTX) For Possible Securities Law Violations, Encourages Investors With Significant Losses to Contact Firm - GlobeNewswireMarch 27, 2022 | globenewswire.comBragar Eagel & Squire, PC Is Investigating Sea, - GlobeNewswireMarch 25, 2022 | benzinga.comBragar Eagel & Squire, P.C. Is Investigating Sea, Cortexyme, and RBB and Encourages Investors to Contact the Firm Get Cortexyme News Delivered to You Automatically Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address J.P. Morgan’s DIRE Warning (Ad)When the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell." Click here to see why Wall Street is in PANIC mode >>> CRTX Media Mentions By Week CRTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRTX News Sentiment▼0.000.61▲Average Medical News Sentiment CRTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRTX Articles This Week▼00▲CRTX Articles Average Week Get Cortexyme News Delivered to You Automatically Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Sangamo Therapeutics News Adverum Biotechnologies News Coherus BioSciences News Scholar Rock News Omnicell News Veradigm News HealthStream News Instil Bio News Protalix BioTherapeutics News BioAtla News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRTX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research.....The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cortexyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cortexyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.